|
Ductal carcinoma in situ of the breast: What is the optimal treatment? |
|---|---|
| รหัสดีโอไอ | |
| Creator | Dolrudee Songtish |
| Title | Ductal carcinoma in situ of the breast: What is the optimal treatment? |
| Publisher | Faculty of Medicine,Srinakharinwirot University |
| Publication Year | 2548 |
| Journal Title | Journal of Medicine and Health Sciences |
| Journal Vol. | 12 |
| Journal No. | 2 |
| Page no. | 1-13 |
| Keyword | DCIS / treatment / breast cancer |
| ISSN | 0859-3318 |
| Abstract | The incidence of early stage breast cancer, including ductal carcinoma in situ (DCIS) has marklyncreased in recent decades due to screening mammogram. The incidence of DCIS has risen from 2-3 % to15-20% of newly diagnosed breast cancer. Because abnormal microcalcifications are the most commonpresentation of DCIS, mammographically guided wire biopsy remains the investigation of choice for obtaininga histological diagnosis. Management options include total mastectomy, excision with radiation and excisionalone. Due to biological and morphological heterogeneity of DCIS, uncertain natural history, and a wide varietyof patient needs, controversy also exists with regard to the optimal management of DCIS patients. Recently manyprospective randomized control studies have not identified independent prognostic factors which are related tooverall survival and recurrence rate in DCIS patients. Despite controversial about benefit of sentinel node biopsyin DCIS, many have recommended its use in high-risk group. Current data suggest adjuvant tamoxifen forreducing local recurrence in estrogen-receptor positive DCIS but not survival benefits. Factors influencing localrecurrence rate and overall survival are likely to be consider for comparative outcome. Studies about factors thatinfluence the local recurrent rate and overall survival rate eg molecular marker and potential drugs includingtamoxifen accompany with third generation aromatase inhibitor for the treatment of DCIS could improve theoutcome of treatment. |
